Facebook (NASDAQ:FB): Evercore Partners has reiterated its Overweight rating on Facebook based on ad targeting improvements, attractive ad pricing, and growing user engagement. Additionally, Evercore lifted its price target to $45 from $34.
MannKind (NASDAQ:MNKD): Summer Street said it is confident that the FDA will not approve MannKind’s Afrezza Dreamboat inhaler — at least without new large clinical trials. The firm, which does not rate the stock, believes the AFFINITY 1 trial was a failure.
Huntsman (NYSE:HUN): Macquarie has upgraded Huntsman to Outperform from Neutral due to valuation and a management focus on ROI. The price target is set for $21.
American Midstream Partners (NASDAQ:AMID): Wells Fargo upgraded American Midstream Partners to Outperform from Market Perform based on the new General Partner sponsor, ArcLight, that should result in accelerated distribution growth and the equity restructuring. The valuation range has been raised to $23-$25 per unit from $19-$21 per unit.